Synaptogenix Files 8-K with Corporate Updates
Ticker: TAOX · Form: 8-K · Filed: Apr 4, 2024 · CIK: 1571934
| Field | Detail |
|---|---|
| Company | Synaptogenix, Inc. (TAOX) |
| Form Type | 8-K |
| Filed Date | Apr 4, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, filing-update
TL;DR
Synaptogenix filed an 8-K on 4/4/24 for corporate updates, including bylaws and financials.
AI Summary
Synaptogenix, Inc. filed an 8-K on April 4, 2024, reporting amendments to its articles of incorporation or bylaws, other events, and financial statements/exhibits. The company, formerly known as Neurotrope Bioscience, Inc., is incorporated in Delaware and headquartered in New York City.
Why It Matters
This filing indicates potential changes in Synaptogenix's corporate structure or governance, which could impact its operational direction and investor relations.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain any immediate negative financial or operational news.
Key Players & Entities
- Synaptogenix, Inc. (company) — Registrant
- Neurotrope Bioscience, Inc. (company) — Former company name
- April 4, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- New York (location) — Principal executive offices
FAQ
What specific amendments were made to Synaptogenix's articles of incorporation or bylaws?
The filing indicates that amendments were made, but the specific details of these amendments are not provided in the summary information.
What are the 'Other Events' being reported by Synaptogenix?
The filing lists 'Other Events' as an item information category, but the specific nature of these events is not detailed in the provided text.
What is the significance of the former company name, Neurotrope Bioscience, Inc.?
Neurotrope Bioscience, Inc. was the previous name of Synaptogenix, Inc., with a date of name change noted as March 12, 2013.
Where are Synaptogenix's principal executive offices located?
Synaptogenix, Inc.'s principal executive offices are located at 1185 Avenue of the Americas, 3rd Floor, New York, New York 10036.
What is the Commission File Number for Synaptogenix, Inc.?
The Commission File Number for Synaptogenix, Inc. is 001-40458.
Filing Stats: 847 words · 3 min read · ~3 pages · Grade level 11.2 · Accepted 2024-04-04 17:00:22
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share SNPX The Nasdaq
Filing Documents
- tm2411084d1_8k.htm (8-K) — 28KB
- tm2411084d1_ex3-1.htm (EX-3.1) — 9KB
- tm2411084d1_ex99-1.htm (EX-99.1) — 10KB
- 0001104659-24-043683.txt ( ) — 227KB
- snpx-20240404.xsd (EX-101.SCH) — 3KB
- snpx-20240404_lab.xml (EX-101.LAB) — 33KB
- snpx-20240404_pre.xml (EX-101.PRE) — 22KB
- tm2411084d1_8k_htm.xml (XML) — 4KB
03 Amendments to Articles of Incorporation or Bylaws
Item 5.03 Amendments to Articles of Incorporation or Bylaws. As previously disclosed, at the annual meeting of the stockholders of Synaptogenix, Inc. (the "Company") held on December 20, 2023, the Company's stockholders approved a proposal authorizing an amendment (the "Certificate of Amendment") to the Company's Amended and Restated Certificate of Incorporation, as amended, to effect a one-time reverse stock split of the Company's outstanding shares of common stock at a ratio of not less than 1-for-8 and not greater than 1-for-25. On April 4, 2024, the Company filed with the Secretary of State of the State of Delaware the Certificate of Amendment to effect a one-time reverse stock split of the Company's common stock, at a ratio of 1-for-25 (the "Reverse Stock Split"). The Reverse Stock Split was effective at 5:00 p.m. Eastern Time, after the close of trading on The Nasdaq Capital Market, on April 4, 2024 (the "Effective Time"). At the Effective Time, every 25 shares of the Company's issued and outstanding common stock were automatically converted into one share of common stock, without any change in the par value per share. In addition, proportionate adjustments will be made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding stock options, warrants and other convertible securities, and to the number of shares issued and issuable under the Company's stock incentive plans. Any stockholder who would otherwise be entitled to a fractional share of common stock created as a result of the Reverse Stock Split will be entitled to receive a cash payment in lieu thereof equal to the fractional share to which the stockholder would otherwise be entitled multiplied by the closing sales price of a share of common stock on April 4, 2024, as adjusted for the Reverse Stock Split. Following the Reverse Stock Split, the shares of common stock will continue to trade on The Nasdaq Capital Market under the symbol "SNPX." The new CUS
01 Other Information
Item 8.01 Other Information. On April 3, 2024, the Company issued a press release announcing the Reverse Stock Split. The press release is filed as Exhibit 99.1 and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. The following exhibits are filed as part of this report: Exhibit Number Description 3.1 Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Synaptogenix, Inc., dated April 4, 2024. 99.1 Press Release, dated April 3, 2024. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SYNAPTOGENIX, INC. Date: April 4, 2024 By: /s/ Robert Weinstein Name: Robert Weinstein Title: Chief Financial Officer